Cytotherapy

Papers
(The H4-Index of Cytotherapy is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles123
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations 89
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial75
Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study52
Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study51
Generating natural killer cells for adoptive transfer: expanding horizons45
Mesenchymal stromal cells from dermal and adipose tissues induce macrophage polarization to a pro-repair phenotype and improve skin wound healing45
Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition43
Adipose tissue and the vascularization of biomaterials: Stem cells, microvascular fragments and nanofat—a review34
Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States33
Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells31
What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings31
Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review and meta-analysis29
Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential29
Advances in generation of three-dimensional skin equivalents: pre-clinical studies to clinical therapies29
Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation29
Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources28
Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation27
The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor–T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma27
Pre-clinical investigation of mesenchymal stromal cell-derived extracellular vesicles: a systematic review27
The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and 27
Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-h26
Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model26
Challenges of manufacturing mesenchymal stromal cell–derived extracellular vesicles in regenerative medicine26
Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes25
Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies25
Autologous bone marrow mesenchymal stromal cell therapy for “no-option” critical limb ischemia is limited by karyotype abnormalities25
0.054842948913574